Wedbush cuts Synageva BioPharma to Neutral in valuation call

|About: Synageva BioPharma Corp. (GEVA)|By:, SA News Editor

Wedbush cuts Synageva BioPharma (GEVA) to Neutral from Outperform.

"We can no longer recommend purchase of GEVA shares at current levels," analyst David Nierengarten says, noting that the stock trades at an EV/2017 sales ratio of 9, well above peers.

Price target is $67.